{"nctId":"NCT00053352","briefTitle":"Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors","startDateStruct":{"date":"2003-11-03","type":"ACTUAL"},"conditions":["Childhood Embryonal Tumor","Childhood Extracranial Germ Cell Tumor","Childhood Extragonadal Germ Cell Tumor","Childhood Malignant Ovarian Germ Cell Tumor","Childhood Malignant Testicular Germ Cell Tumor","Childhood Teratoma","Ovarian Embryonal Carcinoma","Ovarian Yolk Sac Tumor","Stage II Malignant Testicular Germ Cell Tumor","Stage IIA Ovarian Germ Cell Tumor","Stage IIB Ovarian Germ Cell Tumor","Stage IIC Ovarian Germ Cell Tumor","Stage III Malignant Testicular Germ Cell Tumor","Stage IIIA Ovarian Germ Cell Tumor","Stage IIIB Ovarian Germ Cell Tumor","Stage IIIC Ovarian Germ Cell Tumor","Testicular Choriocarcinoma and Yolk Sac Tumor","Testicular Embryonal Carcinoma"],"count":302,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Procedure: conventional surgery","Drug: cisplatin","Drug: etoposide","Biological: bleomycin sulfate","Other: laboratory biomarker analysis"]},{"label":"Arm 2","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"conventional surgery","otherNames":["surgery, conventional"]},{"name":"cisplatin","otherNames":["CACP","CDDP","CPDD","DDP"]},{"name":"etoposide","otherNames":["EPEG","VP-16","VP-16-213"]},{"name":"bleomycin sulfate","otherNames":["Blenoxane","BLEO","BLM"]},{"name":"laboratory biomarker analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Extracranial germ cell tumor that contains 1 of the following malignant histologies: NOTE: Mixed germ cell tumors that include mature/immature teratoma are eligible provided 1 of the 3 histologies listed above is also present in the tumor.\n\n  * Yolk sac tumor\n  * Embryonal carcinoma\n  * Choriocarcinoma\n* Low-risk disease (closed to accrual as of 01/20/10)\n\n  * Stage I gonadal tumors (ovarian and testicular)\n  * Must have undergone complete surgical and radiologic staging to exclude the possibility of \\> stage I disease\n* Intermediate-risk disease\n\n  * Stage II, III, or IV malignant testicular GCT\n  * Stage II or III malignant ovarian GCT\n  * Stage I or II malignant extragonadal GCT\n  * Previously stage I gonadal patients who have relapsed on the low-risk (observation) stratum of this study(closed to accrual as of 01/20/10)\n  * Patients with immature teratoma or mature teratoma who relapse with a malignant component\n* No patients with any of the following diagnoses:\n\n  * Stage IV ovarian and stage III-IV extragonadal GCT\n  * Intracranial GCT\n  * Pure mature or immature teratoma, pure dysgerminoma, or seminoma\n  * Patients with a non-germ cell component in their GCT (e.g., primitive neuroectodermal tumors or rhabdomyosarcoma)\n* Alpha-fetoprotein and beta human chorionic gonadotropin tumor markers known\n\n  * If \\> 5 days have elapsed from the time of obtaining original markers, tumor markers must be repeated before enrollment of low-risk patients and before initiating therapy in intermediate-risk patients (the results of the repeated tumor markers do not have to be known at the time of study enrollment)\n* Must be enrolled within 6 weeks of original diagnostic surgery\n* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR a serum creatinine based on age/gender as follows:\n\n  * ≤ 0.4 mg/dL (for patients 1 to 5 months of age)\n  * ≤ 0.5 mg/dL (for patients 6 to 11 months of age)\n  * ≤ 0.6 mg/dL (for patients 1 year of age)\n  * ≤ 0.8 mg/dL (for patients 2 to 5 years of age)\n  * ≤ 1.0 mg/dL (for patients 6 to 9 years of age)\n  * ≤ 1.2 mg/dL (for patients 10 to 12 years of age)\n  * ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)\n  * ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)\n  * ≤ 1.7 mg/dL (for male patients ≥ 16 years of age)\n* No prior chemotherapy\n* No prior radiotherapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-Free Survival (EFS)","description":"Proportion of patients event free at 3 years following enrollment. Event-free survival is not a primary outcome measure for Arm 2 patients.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Percentage probability of being alive at 3 years following enrollment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Days Hospitalized for Patients Who Receive Chemotherapy","description":"Calculated to quantify the treatment cost associated with this regimen.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.08","spread":"10.27"}]}]}]},{"type":"SECONDARY","title":"Toxicity Associated With Chemotherapy: Grade 3 or Higher. Toxicity as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0","description":"The number of patients assigned to receive chemotherapy that experience CTC Version 4 grade 3 or higher at any time during protocol therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":104},"commonTop":["Neutrophil count decreased","White blood cell decreased","Anemia","Infections and infestations - Other, specify","Febrile neutropenia"]}}}